Paul S. Auerbach, M.D.: advises Lypro on product profiles and clinical strategies. Dr. Auerbach is the Redlich Family Professor of Surgery in the Division of Emergency Medicine at Stanford University School of Medicine and former Chief of Emergency Medicine at Stanford and Vanderbilt Universities. His focus and passion is Emergency Medicine. Along with his clinical activities, he serves as Chief Medical Officer for Healthline Networks and as a Director of NXT Nutritional Holdings. Dr. Auerbach played a critical role as Chief Operating Officer in the early days of KAI Pharmaceuticals. He has served as a Venture Partner for Delphi Ventures. Dr. Auerbach is a graduate of Duke University School of Medicine as well as the Stanford Graduate School of Business.
Peter Calcott, Ph.D.: advises Lypro on manufacturing strategy. Dr. Calcott is a biopharmaceutical manufacturing and supply chain expert. He developed his expertise through work with SmithKline Beecham, Monsanto, Bayer, Immunex, Chiron and PDL. Dr. Calcott has held positions in R&D, Manufacturing, Quality Assurance & Quality Control, Process Development and Corporate Compliance. He is a member of the Board for BayBio. He earned his D.Phil from University of Sussex in the United Kingdom.
Kevin Dwyer: advises Lypro on regulatory issue and development strategies. Mr. Dwyer is the Founding Partner of Pacific BioDevelopment (PBD) a provider of integrated drug development strategies. Prior to founding PBD he worked for Genentech and Monsanto Kevin and the Pacific BioDevelopment team bring regulatory and development expertise to guide our programs.
Leo I. Gordon, M.D.: is our collaborator for our targeted NanoDisk program for treatment of mantle cell lymphoma. Dr. Gordon is the Abby and John Friend Professor of Oncology Research at the Feinberg School of Medicine at Northwestern University where his laboratory focuses on translational research in lymphoma. His laboratory research interest include the biology of reactive oxygen species signaling pathways. Dr. Gordon has served on committees of several national organizations and foundations related to cancer. He has served as co-chairman of the Eastern Cooperative Oncology Group Lymphoma Committee and as chair of the Oncological Sciences Clinical Oncology Study Section at the National Cancer Institute.
Stuart Wren, Business Development: has over 30 years experience in business development and general management, predominately for GlaxoSmithKline (GSK) and its predecessor companies. He serves as Chairman of the Board for the California Antiviral Foundation. Prior to forming Wren International, Mr. Wren led business development efforts in major Asian markets based both in Japan and in London for GSK. In this role, he played a major part in the merger of Nippon Wellcome and Nippon Glaxo. Along with his work with Lypro, Mr. Wren provides corporate development, strategy and alliance management to a number of pharmaceutical companies through Wren International LLC.